Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA Study

Archives of Internal Medicine

Volumn 160, Issue 8, 2000, Pages 1123-1132

  Paredes, Roger ^a   Mocroft, Amanda ^b   Kirk, Ole ^c   Lazzarin, Adriano ^d   Barton, Simon E ^e   Van Lunzen, Jan ^f   Katzenstein, Terese L ^g   Antunes, Francisco ^h   Lundgren, Jens D ^c   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c HVIDOVRE HOSPITAL   (Denmark)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g Rigshospitalet   (Denmark)

^h HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17744418262     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.8.1123     Document Type: Article

References (39)

1. Riddler SA, Mellors JW. HIV-1 viral load and clinical outcome: review of recent studies. AIDS. 1997;11 (suppl A):S141-S148.
2. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996; 334:426-431.
3. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimetre. N Engl J Med. 1996;335:1091-1098.
4. Ioannidis J, Cappelleri JC, Lau J, Sacks HS, Solnik PR. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS. 1996;10:255-262.
5. Galetto-Lacour A, Yerly S, Perneger TV, et al. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J Infect Dis. 1996;173:1388-1393.
6. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
7. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med. 1997;126:929-938.
8. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med. 1997;126:939-945.
9. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
10. Mocroft A, Vella S, Benfield TI, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-1730.
11. Kirk O, Mocroft A, Katzenstein TL, et al. Changes in use of antiretroviral therapy in regions of Europe overtime. AIDS. 1998;12:2031-2039.
12. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications tor clinical management. JAMA. 1998; 279:1984-1991.
13. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 1998;12:1639-1643.
14. Zackin R, Marschner I, Andersen J, et al. Perspective: human immunodeficiency virus type 1 (HIV-1) RNAend points in HIV clinical trials isues in interim monitoring and early stopping. J Infect Dis. 1998;177:761-765.
15. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
16. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science. 1998;280:1871-1872.
17. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12:745-750.
18. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113-F116.
19. Lundgren JD, Phillips AN, Vella S, et al. Regional differences in the use of anti-retrovirals and primary prophylaxis in 3122 European HIV-infected patients. J Acquir Immun Defic Syndr. 1998;17:239-244.
20. Lundgren JD, Pedersen C, Clumeck N, et al. Survival differences in patients with AIDS, 1979-1989. BMJ. 1994;308:1068-1073.
21. SAS Institute Inc. SAS/STAT Users Guide, Version 6. Vol 2. 4th ed. Cary, NC: SAS Institute Inc; 1989.
22. Fiscus SA, Hughes MD, Lathey JL, et al. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type-infected adults treated with nucleosides. J Infect Dis. 1998; 177:625-633.
23. + lymphocyte counts and the risk of progression to AIDS N Engl J Med. 1996; 334:426-431.
24. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-2167.
25. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS. 1998;12:1823-1832.
26. Montaner JSG, De Masi R, Hill A. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS. 1998;12:F23-F28.
27. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic milliliter. N Engl J Med. 1990;322:941-949.
28. 3 (ACTG 175). J Infect Dis. 1998;177:617-624.
29. Mellors J, Japour AJ, Leonard J, et al. Ritonavir (RTV)-saquinavir (SQV) in protease inhibitor-naive patients after 72 weeks. In: Program and abstracts of the 12th World AIDS Conference June-July 1998; Geneva, Switzerland. Abstract 12295.
30. D'armnio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS. 1998;12:1631-1637.
31. Casado JL, Pérez-Elías MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS. 1998;12: F131-F135.
32. Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drags. 1996;52:53-112.
33. + T-cell counts in HIV-infected patients. Ann Intern Med. 1996; 124:1039-1050.
34. Perry CM, Noble S. Saquinavir soft-gel capsule formulation: a review of its use in patients with HIV infection. Drugs. 1998;55:461-486.
35. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999;21:114-119.
36. Kempf DJ, Rode R, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
37. Saag M. What is the role of partially suppressive therapy? clinical and virological failure. Antiviral Ther. 1998;3(suppl 2):4.
38. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-1268.
39. Puig T, Bonjoch A, Ruiz, et al. Usefulness of ritonavir and saquinavir combination therapy for HIV-1 advanced patients failing on indinavir. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September-October 1997; Toronto, Ontario. Abstract 1-201.